Telithromycin: The first of the ketolides

Annals of Pharmacotherapy

Volumn 36, Issue 3, 2002, Pages 452-464

  Shain, Christopher S ^a   Amsden, Guy W ^b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

HMR 3647; Ketek; Ketolides; RU 66647; Telithromycin

Indexed keywords

AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; CLINDAMYCIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; ITRACONAZOLE; KETOCONAZOLE; KETOLIDE; LEVOFLOXACIN; LEVONORGESTREL; MACROLIDE; METRONIDAZOLE; MIDAZOLAM; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIMVASTATIN; TELITHROMYCIN; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; LIVER FUNCTION TEST; MEDICAL LITERATURE; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; KETOLIDES; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 0036194907     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A038     Document Type: Article

References (92)

1. Ketolide: Novel antibacterial agent designed to overcome erythromycin A resistance
2. Pharmaceutical company updates
3. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
4. Synthesis and antibacterial activity of HMR 3647: A new ketolide highly potent against erythromycin-resistant and -susceptible pathogens
5. Novelties in the field of anti-infectives in 1997
6. Aventis pharmaceuticals. Ketolides - An innovative approach to the treatment of respiratory tract infections
7. New research in macrolides and ketolides since 1997
8. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
9. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage
10. Resistance to macrolides-lincosamides-streptogramins and ketolides in staphylococci and streptococci, and new therapeutic strategies
11. HMR 3647: Antibacterial activity and resistance
12. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria
13. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates
14. Resistance to MASK: Mechanisms and potential solutions
15. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
16. Antimicrobial activity of RU-66647, a new ketolide
17. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
18. In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria
19. In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens
20. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin)
21. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies
22. The in vitro activities of ABT-773, telithromycin and other macrolides against Canadian streptococci
23. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status
24. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
25. In-vitro activity of HMR 3647 against Streptococcus pneumonae, Haemophilus influenzae, Moraxella catarrhalis and β-haemolytic streptococci
26. The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent
27. Mechanisms of macrolide resistance in Streptococcus pneumoniae and S. pyogenes from central and eastern European countries
28. Genotype analysis of macrolide resistance and activity of the new ketolide telithromycin on group A, C, and G β-hemolytic streptococci
29. Activity of telithromycin (HMR 3647) against erythromycin-susceptible and -resistant isolates of Streptococcus pneumoniae and S. pyogenes from Austria
30. The comparative in vitro activity of telithromycin against isolates of Streptococcus pyogenes (Lancefield serogroup A) circulating in Great Britain, Northern Ireland and the Republic of Ireland during late 1999
31. Activity of telithromycin against susceptible and well-characterized erythromycin resistant isolates of Streptococcus pyogenes
32. Antibiotic resistance of S. pyogenes and S. pneumoniae strains isolated from infections of outpatients in Germany, 1999-2000
33. Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcusfaecalis
34. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay
35. In vitro activities of ketolides HMR 3647 and HMR 3004, levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis
36. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
37. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
38. Activity of new quinolones, macrolide, and ketolide against 100 strains of Legionella species using broth dilution and intracellular susceptibility testing methods
39. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
40. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae
41. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan
42. In vitro activity of telithromycin (HMR 3647) and seven other antimicrobial agents against anaerobic bacteria
43. In vitro activity of HMR 3647 against anaerobic bacteria
44. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4
45. Telithromycin (TEL): Assessment of susceptibility testing
46. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
47. Activities of antimicrobial agents against intracellular pneumococci
48. In vitro susceptibilities of aerobic and facultative non-spore forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials
49. In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria
50. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae
51. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)
52. Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila
53. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology
54. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans
55. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials
56. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chafeensis
57. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection
58. Oral bioavailability of the ketolide telithromycin (HMR 3647) is similar in both elderly and young subjects
59. Pharmacokinetics of 800-mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers (abstract)
60. Dose proportionality of the pharmacokinetics of telithromycin (HMR 3647), a new ketolide antimicrobial in healthy adult males
61. The bioavailability of telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, is unaffected by food
62. Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses
63. The ketolide antimicrobial, telithromycin (HMR 3647) achieves high and sustained concentrations in alveolar macrophages and bronchoalveolar epithelial lining fluid in healthy Japanese volunteers
64. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects
65. Singledose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects
66. Pharmacokinetic and clinical studies of a new ketolide antimicrobial, telithromycin (HMR 3647) in otorhinolaryngology
67. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils
68. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics
69. Telithromycin (HMR 3647), a new ketolide antimicrobial, is metabolized and excreted mainly in faeces in man
70. Cytochrome P450 (CYP-450) activity is not inhibited in vitro by telithromycin (HMR 3647), a new ketolide antimicrobial
71. Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP)
72. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae
73. Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004
74. Efficacy of telithromycin (HMR 3647), a new once-daily ketolide antimicrobial, provides effective treatment of community-acquired pneumonia
75. Efficacy and tolerability of telithromycin (HMR 3647) vs high-dose amoxicillin in the treatment of community-acquired pneumonia
76. Oral telithromycin (HMR 3647; 800 mg od) is well tolerated and as effective as oral clarithromycin (500 mg bid) in community-acquired pneumonia (CAP) in adults
77. Oral telithromycin (HMR 3647; 800 mg OD) for 7-10 days is well tolerated and as effective as oral trovafloxacin (200 mg OD) for 7-10 days in community-acquired pneumonia (CAP) in adults
78. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with COPD
79. Oral telithromycin (HMR 3647;800 mg od) for 5 days is well tolerated and as effective as cefuroxime axetil (500 mg bid) for 10 days in adults with acute exacerbations of chronic bronchitis (AECB)
80. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute sinusitis
81. Oral telithromycin (HMR 3647; 800mg OD) for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid (500/125mg TID) for 10 days in acute maxillary sinusitis (AMS) in adults
82. Efficacy of 5 days' telithromycin (HMR 3647) vs 10 days' penicillin V in the treatment of pharyngitis in adults
83. Oral telithromycin (HMR 3647; 800mg OD) for 5 days is well tolerated and as effective as oral clarithromycin (250mg BID) for 10 days in group A β-hemolytic streptococcal pharyngitis/tonsillitis
84. Efficacy of the ketolide telithromycin (HMR 3647) in the treatment of bacteremia associated with community-acquired pneumonia
85. Efficacy of telithromycin (HMR 3647), a new ketolide antimicrobial, in community-acquired pneumonia caused by atypical pathogens
86. High in vitro susceptibility of the ketolide telithromycin (HMR 3647) in clinical isolates of key respiratory pathogens
87. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the pharmacodynamics or pharmacokinetics of warfarin
88. Pharmacokinetic profile of telithromycin (HMR 3647) 800mg once-daily in elderly volunteers
89. Telithromycin (Ketek): General safety profile
90. Hepatic effects of Ketek (telithromycin)